33 related articles for article (PubMed ID: 19922840)
1. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
[TBL] [Abstract][Full Text] [Related]
3. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
[TBL] [Abstract][Full Text] [Related]
4. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreiländertreffen 2008, Davos.
Seitz K; Strobel D; Bernatik T; Blank W; Friedrich-Rust M; Herbay Av; Dietrich CF; Strunk H; Kratzer W; Schuler A
Ultraschall Med; 2009 Aug; 30(4):383-9. PubMed ID: 19688670
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.
Coha B; Radmilović K; Gardasanić J; Daković M; Stefanić M; Latić A; Mitrecić D
Acta Clin Croat; 2009 Mar; 48(1):35-9. PubMed ID: 19623870
[TBL] [Abstract][Full Text] [Related]
8. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
9. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
10. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
[TBL] [Abstract][Full Text] [Related]
11. Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?
Nakamoto Y; Nogami M; Sugihara R; Sugimura K; Senda M; Togashi K
Ann Nucl Med; 2011 Feb; 25(2):93-9. PubMed ID: 20957527
[TBL] [Abstract][Full Text] [Related]
12. [Optimizing and adjusting the intravenous contrast medium in the CT diagnosis of the thorax].
Ehritt-Braun C; Ferstl F; Burger D; Krause W; Langer M
Rofo; 1994 Apr; 160(4):364-5. PubMed ID: 8161752
[No Abstract] [Full Text] [Related]
13. Oral and IV contrast agents for the CT portion of PET/CT.
Cronin CG; Prakash P; Blake MA
AJR Am J Roentgenol; 2010 Jul; 195(1):W5-W13. PubMed ID: 20566780
[No Abstract] [Full Text] [Related]
14. PET-CT of extranodal lymphoma.
Metser U; Goor O; Lerman H; Naparstek E; Even-Sapir E
AJR Am J Roentgenol; 2004 Jun; 182(6):1579-86. PubMed ID: 15150013
[No Abstract] [Full Text] [Related]
15. Monitoring lymphoma patients after therapy.
Roschewski M
Clin Adv Hematol Oncol; 2015 May; 13(5):277-9. PubMed ID: 26352768
[No Abstract] [Full Text] [Related]
16. Intravenous Lymphoma Drug Approved.
Voelker R
JAMA; 2017 Nov; 318(17):1644. PubMed ID: 29114818
[No Abstract] [Full Text] [Related]
17. [PET-CT with intravenous contrast in the evaluation of patients with lymphoma. Contribution to diagnostic indications].
Talavera Rubio MP; García Vicente AM; Domínguez Ferreras E; Calle Primo C; Poblete García VM; Hernández Ruiz B; Bellón Guardia M; Palomar Muñoz A; Cepedello Boiso I; Pilkington Woll P; González García B; Cordero García JM; Molino Trinidad C; Soriano Castrejón A
Rev Esp Med Nucl; 2009; 28(5):235-41. PubMed ID: 19922840
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma.
Perry C; Herishanu Y; Metzer U; Bairey O; Ruchlemer R; Trejo L; Naparstek E; Sapir EE; Polliack A
Eur J Haematol; 2007 Sep; 79(3):205-9. PubMed ID: 17662066
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
